profit from every $100 of sales.
$0$100
NeuroSense Therapeutics
$1.78-10.10% today
-90.8% in 1 year
1-year low $1.281-year high $24.80
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What NeuroSense Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$11.1 million of profit last year.
SalesProfit
NeuroSense Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| NeuroSense Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads NeuroSense Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -11 | -12 | -10 | -11 | |
| -11 | -12 | -10 | -11 | |
| -10 | -10 | -10 | -11 | |
| -0.91 | -0.74 | -0.54 | -0.44 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 8 | 3 | 5 | 1 |
| Cash | 4 | 3 | 3 | 0 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 2 | 5 | 2 | 3 |
| 6 | -2 | 3 | -2 | |
| 12 | 14 | 19 | 25 | |
| -143.0% | – | -294.5% | – | |
| -186.7% | 574.6% | -395.3% | 713.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8 | -8 | -10 | -8 | |
| 0 | 0 | 0 | 0 | |
| -8 | -8 | -10 | -8 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 2 | 1 | 2 |
Valuation
- –
- –
- –
- -13.4×
- –
- –
- –
- -227.4%
- -329.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- 465.0%
- 158.4%
- 173,600.0%
- -633.3%
- 434.3%
- –
Growth
- –
- –
- +24.3%
- –
- +23.8%
Financial health
- -0.0×
- -0.11
- 16.5%
- -137.5×
- 0.31
- 0.31
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 888
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 6, 2026 | -0.22 | -0.07 | −210.7% |
| Dec 17, 2025 | -0.11 | – | – |
| May 28, 2025 | -0.11 | -0.10 | −4.8% |
| Apr 7, 2025 | -0.06 | -0.11 | +45.5% |
| Dec 18, 2024 | -0.11 | -0.16 | +31.3% |
| Sep 30, 2024 | -0.02 | -0.20 | +90.0% |
| Apr 5, 2024 | -0.16 | -0.20 | +20.0% |
| Mar 22, 2024 | -0.16 | -0.20 | +20.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
4No pass
Philip Fisher
44No pass
Peter Lynch
–Not enough data
Joel Greenblatt
4No pass
Charlie Munger
54No pass
Terry Smith
51No pass
Questions about NeuroSense Therapeutics
Is NeuroSense Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the NeuroSense Therapeutics AI analysis
What does NeuroSense Therapeutics do?
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. It is in Biotechnology.
Does NeuroSense Therapeutics pay a dividend?
No. NeuroSense Therapeutics does not pay a dividend at the moment.
Is NeuroSense Therapeutics stock halal?
Yes. NeuroSense Therapeutics passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
How has NeuroSense Therapeutics stock done over the past year?
Down 90.8% over the past twelve months, to $1.78. It traded between $1.28 and $24.80 and is 92.8% below its high.
Who are NeuroSense Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with NeuroSense Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.